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Abstract
Interpretation of variants of uncertain significance is an actual major challenge. We addressed this question on a set of
OPA1 missense variants responsible for variable severity of neurological impairments. We used targeted metabolomics to
explore the different signatures of OPA1 variants expressed in Opa1 deleted mouse embryonic fibroblasts (Opa1−/− MEFs),
grown under selective conditions. Multivariate analyses of data discriminated Opa1+/+ from Opa1−/− MEFs metabolic
signatures and classified OPA1 variants according to their in vitro severity. Indeed, the mild p.I382M hypomorphic variant
was segregating close to the wild-type allele, while the most severe p.R445H variant was close to Opa1−/− MEFs, and the
p.D603H and p.G439V alleles, responsible for isolated and syndromic presentations, respectively, were intermediary between
the p.I382M and the p.R445H variants. The most discriminant metabolic features were hydroxyproline, the
spermine/spermidine ratio, amino acid pool and several phospholipids, emphasizing proteostasis, endoplasmic reticulum
(ER) stress and phospholipid remodeling as the main mechanisms ranking OPA1 allele impacts on metabolism. These
results demonstrate the high resolving power of metabolomics in hierarchizing OPA1 missense mutations by their in vitro
severity, fitting clinical expressivity. This suggests that our methodological approach can be used to discriminate the
pathological significance of variants in genes responsible for other rare metabolic diseases and may be instrumental to
select possible compounds eligible for supplementation treatment.
†These authors contributed equally to this work.
Introduction
High-throughput sequencing currently reports myriads of
genetic variants for which pathogenicity is difficult to predict
in the absence of universal functional tests. Metabolomics,
which is closer to the phenotype than any other ‘omics,’ may
be particularly relevant for such fine pathogenicity prediction.
More than 400 pathogenic variants have been reported in
OPA1 (Optic Atrophy 1) gene (http://opa1.mitodyn.org) (1, 2),
responsible for optic nerve degeneration and visual loss, ranging
from isolated ‘Dominant Optic Atrophy’ (DOA; OMIM #165500) to
more severemulti-systemic syndromes named ‘DOAplus’ (OMIM
#125250), including some bi-allelic cases with Behr Syndrome
(OMIM #210000). OPA1 encodes a dynamin-related GTPase driv-
ing the efficiency of energy production through its multiple
roles in mitochondrial dynamics and ultrastructure (3–6), mito-
chondrial DNA (mtDNA) maintenance (7–9), apoptosis (10), cal-
cium fluxes (11), oxidative stress (12), mitophagic flux (13–15),
and more generally in mitochondrial plasticity and quality con-
trol (16–18), all these functions being affected when OPA1 is
mutated.
The severe DOAplus syndromes, affecting about 20% of
patients, involve extraocular features such as sensorineural
deafness, ataxia, peripheral neuropathy and chronic progressive
external ophthalmoplegia with mitochondrial myopathy and
mtDNA instability (19). Additional neurological phenotypes,
such as spastic paraplegia (19), multiple sclerosis-like syndrome
(20), parkinsonism and dementia (21), have also been related
to dominant OPA1 variants. More recently, the severe early
onset Behr (22–24), MELAS-like stroke (25) and Leigh-like (26)
syndromes, as well as syndromes involving cardiomyopathy
(27), were associated with biallelic OPA1 inheritance (for reviews
see 17, 28).
The relationships between OPA1 variants and their clini-
cal consequences remain largely unknown. Only two clear cut
genotype/phenotype correlations have been established so far:
one concerns the higher severity of missense mutations in the
GTPase and dynamin domains than those leading toOPA1haplo-
insufficiency (19). For instance, the p.R445H variant has been
associated with severe dominant forms of the disease (29). The
second is related to OPA1 bi-allelic inheritance leading to severe
encephalopathy with, sometimes, early death of the patients.
Although a few cases of homozygous variants were reported,
the majority of clinical presentations associated with bi-allelic
inheritance are related to the association of an OPA1 pathogenic
variants with a rather frequent p.I382M hypomorphic OPA1 vari-
ant, which by itself, either in heterozygous or homozygous state,
has almost no clinical consequence (22–24, 30).
To better understand the impact of OPA1 pathogenic variants
on mitochondrial functions, we cloned mutated cDNAs of the
human OPA1 isoform 1 (ISO1), and stably expressed them in
Opa1−/− MEFs (31). These isogenic cell models revealed that
the p.D603H variant, associated with isolated optic atrophy,
exhibitedmildly reduced respiration and complexVdisassembly
with increased mitochondrial network fragmentation. The most
severe p.G439V and p.R445H variants, associated with DOAplus
displayed a complete mitochondrial network fragmentation,
severe energetic impairment and mtDNA depletion. Conversely,
the hypomorphic p.I382M variant alone failed to manifest
any significant mitochondrial alteration, under normal growth
condition in high-glucose medium (31).
Here, we used a targeted metabolomics approach to re-
examine this collection of isogenic cells bearing OPA1 wild-type
and pathogenic variants in glucose-free medium supplemented
with galactose, a growth condition forcing the oxidative
metabolism (32). We evidenced a clear correlation between
the metabolomic signature of each mutation, including the
hypomorphic p.I382M variant, with their in vitro phenotype,
overall fitting the clinical severity, thus predicting with high
resolution their pathogenicity and clearly discriminating among
the different missense variants.
Results
Metabolomics analysis
Weused a targetedmetabolomics approach on Opa1+/+,Opa1−/−
MEFs and five Opa1−/− MEFs expressing human WT or mutated
ISO1 OPA1, grown for 24 h in galactose medium. After validation
of the quality control (QC) and considering the dynamic range
for eachmetabolite, 129 out of 188 (68.6%) metabolites were con-
served for statistical analyses (Supplementary Table S1). First
plan of the principal component analysis (PCA) showed that
sample normalization was accurate to overcoming batch effect
(Supplementary Fig. S1). The first principal plan of the PCA with
all seven groups of MEFs showed a clear discrimination between
groups with the first and the second principal components
(PC1 and PC2), accounting for more than 68% of the total data
covariance (Fig. 1). PC1 accounts for 51.3% of the total covari-
ance and when samples are projected to this PC groups are
distinctively separated according to the function of OPA1 gene
and the impact different isoforms have on the clinical presen-
tation of the disease based on genotype-phenotype correlation.
PC2 captures 17.1% of the total covariance and when the sam-
ples are projected into this component, MEFs transfected with
human OPA1 has positive coordinates (positive score values)
whilst MEFs with native murine Opa1 gene have negative score
values suggesting an effect of the transfection experience on
MEF metabolic phenotype. Independence of these two factors
(impact of gene mutation and transfection) on the metabolome
is verified here by the orthogonality of PCs.
As expected from the PCA, the supervised orthogonal projec-
tions to latent structures discriminant analysis (OPLS-DA) (not
shown) model separated Opa1+/+ and Opa1−/− samples with
excellent predictive capabilities and very low risk of overfitting
(Q2Ycum =0.99; Q2Y cum-perm =−0.82 and P-value CV-ANOVA =1.35e-
5). Important metabolites contributing to this model according
to their variable importance in projection (VIP) and loadings
are represented in Figure 2. Metabolic signature was essentially
composed by relatively diminished concentration in MEF bear-
ing deleted Opa1 gene of 15 out of 20 quantified amino acids,
the indicator of collagen turnover trans-4-hydroxyproline and 3
other biogenic amines: taurine, methionine sulfoxide (Met-SO)
and the polyamine spermidine. Glutamine was the only amino
acid found relatively increased in Opa1−/− MEF fibroblasts while
the polyamine spermine was found also relatively increased
in these cells. Concerning lipid molecules, there exists a deep
phosphatidylcholine (PC) remodeling with rather decreased PCs
concentration in Opa1−/− MEF whilst the opposite is observed
with sphingomyelins (SM), except for SM 16:1. Lysophosphatidyl-
cholines (lysoPC) even when participating to the metabolic sig-
nature did not behave as a single class and some lysoPC were
found relatively increased while other relatively decreased in
Opa1−/− MEF.
When only Opa1−/− MEFs with transfected human OPA1 iso-
forms were studied, the first two PC explained 65.5% of the total
covariance in the X matrix (containing only metabolomic data
from transfected isoforms),with PC1 and PC2 accounting for 52.5
Figure 1. First principal plan of the PCA. When samples are projected into the first principal component (PC1) different isoforms are well separated according to their
proximity to Opa1+/+ (black circles) or Opa1−/− (red circles) which have opposite coordinates in PC1 and represent normal and totally deleted Opa1 gene, respectively.
Two subgroups are less well separated though: transfected human normal isoform (ISO1, gray circles) from I382M (blue circles) variant and R445H (brown circles) variant
from totally deleted murine Opa1−/− MEF. When projecting samples into the second PC (PC2) non-transfected MEF (Opa1+/+ and Opa1−/−) cannot be separated from
each other but plot far away from the projection of transfected MEFs in PC2, indicating a possible effect of transfection. Samples transfected with D603H and G439V
isoforms have been represented as green and pink circles, respectively.
and 13%, respectively (Figure 3A). Out of 5, 4 groups formed by
OPA1 isoforms were unambiguously distinguished in the first
component of the PCA. Indeed, only ISO1 (wild-type allele) and
p.I382M isoforms were not clearly separated one another in this
component. To tackle the relation depicted by the PCA, an unsu-
pervised method that ignores any response vector, we decided
to build a supervised OPLS model considering coordinates in
PC1 (called scores or t1 values) as the quantitative Y vector. We
also calculate Spearman correlation coefficient between t1 and
each metabolite in the X matrix. As expected from the PCA,
the predictive latent variable (pLV) of the OPLS model correlated
very well with the expected Y vector (not shown). This model
had excellent predictive capabilities and the risk of overfitting
was very low (Q2Ycum =0.99.; Q2Y cum-perm =−0.34 and P-value
CV-ANOVA =2.9e−28). Important metabolites for the explanation
of Y vector (i.e. t1 scores as indicators of group separation)
are represented as a volcano plot combining univariate and
multivariate analysis with Spearman ρ correlation coefficient in
the x-axis and VIPs of the OPLS model in the y-axis (Figure 3B).
Concentration of 17 out of 20 amino acid correctly measured
were higher in the fibroblasts carrying OPA1 isoforms associ-
ated to more severe clinical phenotype (p.G439V and p.R445H).
When the metabolic phenotype was oriented toward Opa1−/−
metabolic phenotype, concentrations of trans-4-hydroxyproline,
taurine,methionine sulfoxide and the lowprotonated polyamine
putrescine decreased whilst the concentration of the highest
protonated spermine increased. As the metabolome get closer
to the Opa1−/− metabolic phenotype concentration of 23 PCs,
2 SMs, 3 lysoPCs and acetyl-carnitine (C2) decreased whilst the
concentration of 11 PCs and 4 SMs increased.
OPLS model shared 44 (67%) important metabolites with the
OPLS-DAmodel discriminating Opa1+/+ from Opa1−/− −carrying
MEFs. All metabolic signatures of OPA1 variants shared a
global amino acids reduction and lipid remodeling, comprising
phosphatidylcholines, sphingomyelins and lysophosphatidyl-
cholines. The regression plots in Figures 4 and 5 represent
the linear regression between scatter plot coordinates of the
first principal component of the PCA or t1 (x-axis) and the
relative concentrations, sums or ratios of metabolites (y-axis)
of the most important polar metabolites and lipids found in
both multivariate supervise models. Figure 4 suggests that
spermine concentration increases with t1 (i.e. whilst the
isoform-associated metabolic profile gets closer to the Opa1−/−
profile and farthest from the Opa1+/+ profile) and in Opa1−/−
compared to Opa1+/+ cells, while less protonated polyamines
(putrescine and spermidine) are relatively decreased, while
trans-hydroxylated proline (t4-OH-Pro) relative concentrations
parallel that of amino acids concentrations.
Figure 5 reports the lipids’ data, showing a linear increased
ratio of two sphingomyelins (SM18:0 and SM16:0) and hydrox-
ylated sphingomyelins (SM:OH 22:1 and SM:OH 22:2) with t1.
Conversely, the absolute concentration of polyunsaturated dia-
cyl phosphatidylcholines (PUFA aa) as well as that of the ratio
between polyunsaturated and monounsaturated (MUFA aa) dia-
cyl phosphatidylcholines decrease with t1. For acyl-alkyl (ae)
species, we also observed a decrease in the MUFA to SFA (sat-
urated fatty acid) ratio with t1.
Discussion
Our study provides compelling evidences for the high power of
metabolomics to establishing and hierarchizing the pathogenic-
ity of OPA1 genetic variants expressed in an isogenic genetic
background deleted for the endogenous Opa1. This strong
Figure 2. Volcano plot (loadings versus VIP) from the OPLS-DA model comparing murine Opa1+/+ and Opa1−/− MEF. Only most important metabolites, i.e. those with
VIP≥1, have been labelled. Negative loadings indicate relatively decreased metabolite concentrations in Opa1−/− compared to Opa1+/+ MEF. Main features of the
metabolomic signature are decreased level in Opa1−/− MEF of many dialkyl and acyl-alkyl (PC aa and PC ae) phosphatidylcholine species (orange bubbles), almost all
amino acids (green bubbles), some biogenic amines (blue bubbles) including spermidine, trans-hydroxyproline (t4-OH-Pro), taurine and methionine-sulfoxide (Met-SO)
along with lysophosphatidylcholines (lysoPC, brown bubbles) with acyl chain length of less than 22 carbons. On the other side, many sphingomyelins (SM, yellow
bubbles), mainly hydroxylated (SM(OH)), some phosphatidylcholine species, the highest order polyamine spermine and lysophosphatidylcholines species with acyl
chain with more than 22 carbons were found increased in Opa1−/− compared to Opa1+/+ MEF. Glutamine was the only amino acid relatively increased in Opa1−/−
MEF. Legend: Ala, alanine; Asn, asparagine; Asp, aspartate; Gln, glutamine; Gly, glycine; His, histidine; Ile, isoleucine; Met, methionine; Phe, phenylalanine; Pro, proline;
Ser, serine; Thr, threonine; Trp, tryptophan; Val, valine. For phosphatidylcholines, the sum of the length of the two acyl or acyl–alkyl groups is noted after the C and is
followed by the number of double bonds. The same notation is used for representing the length and the number of double bonds in the acyl chain of sphingomyelins
and lysophosphatidylcholines.
predictability is essentially related to the statistical power of
metabolomics, to the fact that all variants were expressed
into the same nuclear background, rendering profiles highly
comparable and to the growth condition in galactose that
exacerbates mitochondrial dysfunctions. Indeed, as already
reported, the absence of glucose and the presence of galactose
restrict glycolysis rate and promote ATP production by the
mitochondrial respiration (32). Under these conditions, cells
exhibiting mitochondrial defects are slowly growing and more
vulnerable to cell death (33).
PCA of themetabolome including MEF with Opa1+/+,Opa1−/−
genes and transfected with human OPA1 isoforms (Fig. 1) strati-
fied the metabolomic signatures of the OPA1 variants according
to their progressive order of pathogenicity. It should be stressed
that PCA is an unsupervisedmethodmeaning that sampleswere
grouped on the basis of their metabolic profile by the algorithm
with no integration of the severity parameter when constructing
latent variables (i.e. principal components). As expected from
the PCA results, excellent predictive models were e further evi-
denced using the supervised OPLS(−DA) approaches, integrating
PCA score of the first PC or t1 as a proxy for clinical severity (for
the OPLS model). These supervised models enabled identifying
the most discriminating metabolites with respect to the clinical
severities.
Furthermore, the power of the metabolomics analysis
allowed to precisely assess how much the different MEF cell
lines differ from the ISO1control, containing the wild-type
human cDNA, and from the Opa1−/− background, considered
as the maximal pathogenic condition. Indeed, the p.R445H
variant, responsible for the most severe syndromic phenotypes,
turned out to be the closest to Opa1−/− genotype, behaving
almost as a null allele. In contrast, the hypomorphic p.I382M
variant, almost without pathological consequence by itself (22–
24), plots very close to ISO1 in t1 but was not significantly
different (P-value=0.056, Wilcoxon test) in this latent variable.
Through this discrete though no significant shift of I382M
MEFs samples to the right of ISO samples (higher t1 scores)
and toward dysfunctional variants metabolomics proves to
be highly sensitive to the impact OPA1 function has on cell
metabolic phenotype.This result found in vitro perfectlymatches
with clinical practice where I328M alone is not correlated
with optic atrophy. It’s also reasonable to expect an overt
metabolic distinction between I382M and ISO MEFs with an
increased samples size. This finding is encouraging because, in
a previous study, we were unable to identify any biochemical
data distinguishing MEFs carrying this hypomorphic variant
from ISO1 MEFs, since neither the mitochondrial network, nor
the respiratory activity or the mtDNA were altered, in contrast
with what we observed for the other pathogenic variants (31).
Noteworthy, targeted metabolomics analysis of fibroblasts from
a cohort of DOApatients failed to reveal any significant signature
(34), while we did evidence a specific signature involving the
purine metabolism in patients’ plasma, but without being able
to discriminate the different OPA1 mutations examined (35).
Figure 3. Scatter plots of the PCA first principal plan (A) and the Spearman correlation coefficient (ρ) versus VIP (B) comparing MEF metabolomes transfected with
five human OPA1 variants. (A) Out of 5, 4 groups are easily distinguishable in the first principal component (PC1): ISO1- I382M, D603H, G439B and R445H. No group
discrimination can be seen in the second principal component (PC2). (B) Spearman correlation coefficients (ρ) where obtained from the non-parametric correlation
between sample’s scores in the first principal component or t1 in (A) and each metabolite concentration whilst VIP comes from the OPLS model. Only most important
metabolites, i.e. those with VIP≥ 1, have been labelled. For a given metabolite, negative values of ρ indicate negative correlation between its concentration and t1 (i.e.
metabolite concentration are relatively close to Opa1+/+ MEF concentration and relative far from Opa1−/− MEF concentration) whilst a positive ρ value indicates the
opposite situation (i.e. metabolite concentration are relatively close to Opa1−/− MEF concentration and relative far from Opa1+/+ MEF concentration. Main features of
the metabolomic signature are decreased level of many dialkyl and acyl-alkyl (PC aa and PC ae) phosphatidylcholine species (orange bubbles), almost all amino acids
(green bubbles), some biogenic amines (blue bubbles) including taurine, putrescine, trans-4-hydroxyproline (t4-OH-Pro) and methionine-sulfoxide (Met-SO) along with
three lysophosphatidylcholines (lysoPC, brown bubbles) and two sphingomyelins (SM, yellow bubbles). On the other side, four sphingomyelins (SM, yellow bubbles),
two of them hydroxylated (SM(OH)), some phosphatidylcholine species and the highest order polyamine spermine were found to increase while approaching the
metabolomic signature of Opa1−/− . Legend: Ala, alanine; Arg, arginine; Asn, asparagine; Asp, aspartate; Gly, glycine; His, histidine; Ile, isoleucine; Leu, leucine; Lys,
lysine; Met, methionine; Phe, phenylalanine; Pro, proline; Ser, serine; Thr, threonine; Trp, tryptophan; Ser, serine; Val, valine. For phosphatidylcholines, the sum of the
length of the two acyl or acyl–alkyl groups is noted after the C and is followed by the number of double bonds. The same notation is used for representing the length
and the number of double bonds in the acyl chain of sphingomyelins and lysophosphatidylcholines.
Thus, only the combined use of metabolomics and MEFs
expressing OPA1 alleles proves to be valid for highlighting
metabolic changes discriminating genetic variants. From our
results, this is expected to be truth even for the hypomorphic
p.I382M allele, for which the pathogenicity remains questionable
to date.
From these signatures classifying the variants according to
their severity, we isolated the most discriminating metabolites
responsible for generating this hierarchy, which consisted in
the increase in spermine/spermidine ratio and the decrease
of the sum of amino acids, t4-OH-Pro, SM OH 22:1, SM OH
22:2, SM 18:0/SM16:0 ratio, PC PUFA aa, PC PUFA/MUFA aa, PC
MUFA/SFA ae ratios. Such a decrease in all amino acids was
already observed in fibroblasts from patients with the Leber
Hereditary Optic Neuropathy (LHON), the other major form of
mitochondrial optic neuropathy, witnessing an ER stress with
impairment of protein synthesis due tomitochondrial deficiency
(34). This might be related to the fact that protein synthesis is
one of the most energy-consuming cellular processes, or be a
consequence of an alteration of the autophagic process (15).
The decreased concentrations of hydroxyproline found here is
in full agreement with this hypothesis since hydroxyproline
levels reflect the turnover of collagen, which synthesis is
one of the main fibroblast functions. The deregulation of
polyamines (putrescine, spermine and spermidine) metabolism,
also observed in the optic nerves of the Opa1+/− mouse model
(36), in LHON fibroblasts (34) and in glaucoma patients (37),
is known to be related with mitochondrial deficiency, and
plays a crucial role in the post-translational processing of the
eIF5A translation factor, by activating the protein translation
activity (38). Therefore, the mitochondrial dysfunction related to
OPA1 mutations and the associated patho-mechanism could be
related to a protein synthesis stress, through the alteration of
polyamines metabolism and eIF5A maturation.
The other main alteration disclosed here concerns the phos-
pholipid profiles. The increased concentrations of two hydrox-
ylated sphingomyelins (SM OH 22:1, SM OH 22:2), as well as
those of the SM18:0/SM16:0 ratio are highly predictive of variants
severity. SMs play a crucial role in membrane structure and
function, i.e. by forming lipid raft in association with cholesterol,
by acting as second messengers themselves, by their enzy-
matic transformation in other highly informative molecules like
ceramides, and by their contribution to myelin sheath composi-
tion. Little is known about cellular functions of the specific sph-
ingomyelin species identified in this study. Nevertheless, SM18:0
specifically plays a role in protein export by acting as the natural
ligand of p24 proteins (39). These p24 proteins facilitate cargo
transport from ER to the Golgi apparatus, and under endoplas-
mic stress the increased SM18:0 concentration might contribute
to ER relief, by enhancing cargo transfer to the Golgi apparatus.
In our study, the levels of SM(OH) 22:1 and SM(OH)22:2 increased
with the clinical severity of the OPA1 mutations. Correlation
between SM(OH)22:1 and SM(OH)22:2 concentrations observed
here has been already described in a physiological context and
was imputed to sphingolipid-specific desaturase activity (40).
The biological meaning of this variation is unclear in the context
of OPA1 dysfunction and to the best of our knowledge, the
specific roles of these hydroxyl-sphingomyelin species have not
been explored in any other pathology, so far. The increased
SMs concentrations we observed is in apparent contradiction
with what we have previously found in the Opa1+/− mouse
optic nerve,where 10 sphingomyelinswere decreased (36). These
opposite results may reflect the differences between the tissues,
with probably different pathways activation for sphingomyelin
synthesis and catabolism in retinal ganglion cells and fibrob-
lasts. Nevertheless, all our studies point to an alteration of
sphingomyelin metabolism that needs to be further investi-
gated as far as sphingomyelins play crucial roles in myelination
Figure 4. Regression and box plots for polar metabolites. Relative metabolite concentrations for the sum of amino acids (upper panel), trans-4-hydroxyproline (t4-OH-
Pro) (middle panel) and the ratio spermine to spermidine (downer panel) have been linearly regressed with t1 (scores of PC1 of the PCA for transfected cells) (left) or
represented as a box plots for Opa1+/+ and Opa1−/− MEFs (right). In MEFs transfected with human isoforms of OPA1 gene, regression lines have been drawn along
with their respective determination coefficients (R2). Amino acid and t4-OH-Pro linearly decrease whilst spermine synthase activity,measured by spermine/spermidine
ratio, linearly decreases with t1 (i.e. whenmetabolic phenotype approaches Opa1−/− and get far away from Opa1−/− phenotypes). These changes are obviously verified
in Opa1+/+ and Opa1−/− MEFs. In regression plots, the following color code has been used: ISO1 (gray); I382M (blue); D603H (green); G439V (pink) and R445H (brown).
In box plots Opa1+/+ (WT) box has been colored in dark gray whilst red was used for Opa1−/− boxes.
Figure 5. Regression and box plots for lipid metabolites. Upper panels: relative metabolite concentrations for hydroxy sphingomyelins SM OH 22:1 and SM OH 22:2
(upper middle and right panels, respectively) and the ratio between octadecanoyl (SM 18:0) and hexadecanoyl (SM 16:0) sphingomyelins (upper left panel) have been
linearly regressed with t1 (scores of PC1 of the PCA for transfected cells) or represented as box plots for Opa1+/+ and Opa1−/− MEFs (bottom position in each panel). As
for polar metabolites, in MEFs transfected with human isoforms of OPA1 gene, regression lines have been drawn along with their respective determination coefficients
(R2). There exists a clear parallel increasing between the two structurally close related SM OH 22:1 and SM OH 22:2 and t1. Also, the proportion of SM 18:0 seems to
increase when the metabolic phenotype approaches that of Opa1−/− compared to the concentration of SM 16:0. Bottom panels: the sum of polyunsaturated diacyl
phosphatidylcholines (PUFA aa) (bottom left) and the ratios between PUFA aa and monounsaturated diacyl phosphatidylcholines (PUFA/MUFA aa) (bottommiddle) and
between monounsaturated and saturated fatty acids in the alkyl-acyl family (MUFA/SFA ae) (bottom right) decrease linearly with t1. As expected these changes are
verified in Opa1+/+ (WT) and Opa1−/− MEFs. In regression plots, the following color code has been used: ISO1 (gray); I382M (blue); D603H (green); G439V (pink) and
R445H (brown). In box plots Opa1+/+ (WT) box has been colored in dark gray whilst red was used for Opa1−/− boxes.
and in the pathophysiology of mitochondrial optic neuropathies
(41).
As for other different models of OPA1 dysfunction previously
studied (34, 36, 42), we found that the phosphatidylcholines’
concentrations were also highly altered. The most discrimi-
native features of variant severity were the decrease of the
sum of polyunsaturated diacyl phosphatidylcholines (PUFA aa)
and a decreased saturation of the diacyl phosphatidylcholines
(PUFA/MUFA aa ratio) and alkyl species (MUFA/SFA ae). As phos-
phatidylcholines are the most important components of cell
membranes, our observations suggest that membrane remod-
eling due to the alterations of mitochondrial dynamics and to
the ER stress could affect the biosynthesis and transport of
phospholipids between these two cellular compartments. Inter-
estingly, decreased concentration of unsaturated phospholipids
in cellular membranes was shown to trigger endoplasmic stress
through non-classical pathways (43).
To conclude, the combination of the metabolomic approach
with the analysis of OPA1mutated alleles expressed in the Opa1
knock-out MEF model allowed to accurately classify and hierar-
chize OPA1 variants according to their pathogenicity, clearly dis-
criminating among the different missense variants. This strat-
egy may further represent a relevant tool to predict the progres-
sion of the disease, to identify therapeutic targets and to assess
readily their efficiency as surrogate biomarkers. Ultimately, this
versatile approach could be useful for any rare disease related to
metabolic perturbations.
Materials and Methods
Cells and culture conditions
MEFs with their native Opa1 endogenous gene (Opa1+/+), MEFs
with deleted Opa1 gene (OPA1−/−) and Opa1−/−MEFs transfected
with the human wild-type OPA1 isoform 1 (the original tran-
script identified, RefSeq: NM_015560.2, ISO1), or human OPA1
isoform 1 carrying c.1146A>G (p.I382M), c.1316G>T (p.G439V),
c.1334G>A (p.R455H) or c.1807G>C (p.D603H) pathogenic vari-
ants, previously described in (31, 44, 45) were used. The retroviral
expression vector was co-transfected with the ecotropic retro-
viral packaging vector pCLEco into Hek 293 T cells. Retroviral
stocks were harvested 48 h after transfection and used to infect
MEF cultures. To achieve a stable cell pool, the selection with
antibiotic puromycin lasted as long as the control (untrans-
duced) cells completely die (7–10 days). The concentration of
the antibiotic in culture was then reduced and, after 1 month,
was removed entirely. The antibiotic selection with low con-
centration of puromycin was cyclically performed and the OPA1
expression in cells was regularly checked.
MEFs were grown in a high-glucose (25 mM) Dulbecco’s
modified Eagle medium (DMEM, Life Technologies) supple-
mented with 10% fetal bovine serum (FBS, South America, Gibco,
Life Technologies), 2 mM L-glutamine, 100 U/ml penicillin and
100 μg/ml streptomycin, in an incubator with a humidified
atmosphere of 5%CO2 at 37◦C.Twenty-four hours before harvest-
ing, cells were grown in glucose-free DMEM (Life Technologies)
supplemented with 5 mM galactose, 2 mM L-glutamine, 5 mM
sodium pyruvate and 5% FBS (DMEM-galactose).
Metabolites extraction
For each cell line, samples were collected in quintuplicate.
When approximately 70% confluence was reached, the culture
mediums were removed, and cells were washed twice in ice-
cold phosphate-buffered saline (PBS) solution and harvested by
scraping. The supernatants were discarded after centrifugation
(3000 g for 5 min at 4◦C) and the cell pellets were resuspended
in 400 μl of ice-cold PBS solution, and centrifuged again in the
same conditions.The supernatantwas discarded, and the pellets
immediately frozen by throwing in liquid nitrogen for 5 min and
then stored at −80◦C until analysis. Metabolites extraction was
performed by adding 100 μl of ice-cold ethanol/PBS (85:15, v/v)
solution to the cell pellets. After vortexing, the mixture was
transferred to a 0.5 ml homogenizer tube prefilled with ceramic
beads. Cell lysis were achieved in a Precellys®24 homogenizer
(Bertin instruments, Montigny-le-Bretonneux) by two cycles of
grinding (40 sec at 6500 rpm, followed by 30 sec at 6000 rpm)
at 4◦C. The resulting homogenates were centrifuged at 20000 g
for 10 min at 4◦C and the supernatants stored at −80◦C until
analysis.
Metabolomics analysis
Weapplied a targeted,quantitativemetabolomic approach to the
cell extracts using the Biocrates technology (AbsoluteIDQ® p180
kit, Biocrates Life sciences) in an AB Sciex QTRAP 5500 (Life Sci-
ences SCIEX)mass spectrometer. Sampleswere prepared accord-
ing to the Biocrates Kit User Manual. Briefly, after thawing on ice,
10 μl of each sample (cell-lysate homogenate supernatants) were
added to the center of the filter placed on the upper wall of the
well in a 96-well plate. Metabolites were extracted in a methanol
solution using ammonium acetate after drying the filter spot
under nitrogen flow and derivatizingwith phenylisothiocyanate.
The extracts were finally diluted with mass spectrometry run-
ning solvent beforemass spectrometry analysis. This kit enables
quantification of up to 188 different endogenous molecules,
including acyl-carnitines (40), amino acids (21), biogenic amines
(21), glycerophospholipids (90), sphingolipids (15) and sugar (1).
Flow-injection analysis (FIA-MS/MS) was used for quantifying
acyl-carnitines, glycerophospholipids, sphingolipids and sugar,
whereas liquid chromatography (LC) allowed the separation of
amino acids and biogenic amines prior to detection with mass
spectrometry (LC-MS/MS).
Data cleaning and normalization
After validation of the three levels of QCs used in the kit and
before statistical analysis, the raw data were examined to
excludemetaboliteswithmore than 20% of concentration values
below the detection limit. Since the samples were analyzed
in two different batches, to account for batch effect, the five
Opa1+/+ samples were analyzed in both batches and one of them
was used to normalize all the samples in each batch (sample
normalization). The effectiveness of sample normalization was
then verified using PCA on the remaining eight WT samples.
Metabolite concentrations in each sample were then normalized
with respect to the total sum of metabolites in the given sample
(row normalisation). Row normalisation avoids finding spurious
between-samples differences merely due to differences related
to the number of cells collected for each sample.
Statistical analyses
Relativemetabolite concentration betweenOpa1+/+ andOpa1−/−
were compared using non-parametric Mann-Whitney-Wilcoxon
test.
Metabolites were scaled to have zero mean and unit variance
scaling before submission to unsupervised and supervised algo-
rithms. PCA was used as an unsupervised approach for outlier
detection, based on Hotelling’s T2 distance, and identification
of similar samples grouping together in the scatter plot. In
the supervised analysis the X matrix of predictive variables
was composed of metabolite concentrations. We applied two
supervised analyses: orthogonal projection to latent structures
(OPLS) alone and associated to discriminant analysis (OPLS-DA).
In the OPLS-DAmodel,Opa1+/+ andOpa1−/− MEFswere included
in the Y vector as qualitative attributes. In the OPLS model
sample coordinates of the five human transfected isoforms (i.e.
ISO1, p.I382M, p.D603H, p.G439V and p.R445H) in the first prin-
cipal component (PC1) was considered as the quantitative pre-
dicted variable (Y vector) whilst the X matrix was as before the
metabolite concentrations. To avoid selecting optimistic over-
fitted models, predictive capabilities of the final OPLS (DA) mod-
els were evaluated by cross-validation using cross-validated R2Y
(Q2Ycum or goodness of prediction), cross-validated analysis of
variance (CV-ANOVA) test and the goodness of prediction of
permutedmodels (Q2Ycum-perm).Modelswith a lowdegree of over-
fitting are characterized by Q2Ycum> 0.5, negative Q2Y cum-perm
and are significantlymore discriminant than the nullmodel (CV-
ANOVA P-value< 0.05). In OPLS-DA predictive model, selection
of metabolites of interest was made through the combination
of two pieces of information: VIP and the loading between the
metabolite in the Xmatrix and the pLV(s) of the OPLS-DAmodel.
Only metabolites with a VIP value larger than 1 and (abso-
lute) high loading values were considered as important in the
metabolomics signature. In the OPLS model, the volcano plot
was formed by Spearman ρ correlation coefficients calculated
between PC1 and each metabolite in the x-axis and VIPs in the
y-axis. This way, we put together univariate and multivariate
analysis in one plot, both capturing agreement betweenmetabo-
lite concentration and latent variables. More information about
PCA- and PLS-based methods can be found in ‘Supplementary
information: multivariate statistical analysis.’
Supplementary Material
Supplementary Material is available at HMG online.
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